Contract development company MedPharm has announced a new fast track service for topical formulation development, including for respiratory delivery. The company offers development services for a variety of OINDP formulations, including MDIs, DPIs, inhalation solutions, and nasal sprays. According to the announcement, the service “produces a safe and stable, but ultimately non-optimized formulation” for proof of concept testing within months.
MedPharm CEO Andrew Muddle said, “We have added this service to help some of our clients who wish to progress their product into human trials as soon as possible, and take advantage of the early generation of clinical data. They can now do so with MedPharm’s new Formulation Fast Track Service, a specialist service to speed up the development of topical formulations and advance them to the clinic in as little as 4 months. By accepting inherent risks, our clients can take advantage of MedPharm’s expertise to quickly achieve the ultimate proof of concept for their formulation; a first in human clinical trial.”
The company opened a new GLP laboratory at its Guildford, UK headquarters in May of last year.
